In Brief: Breast implant litigation
This article was originally published in The Gray Sheet
Executive Summary
Breast implant litigation: Louisiana state court in New Orleans postpones until Jan. 7 Phase II of the first class action silicone breast implant trial against Dow Chemical while the federal Sixth Circuit Court of Appeals in Cincinnati decides on a writ of mandamus submitted last summer by Dow. The writ seeks reversal of a ruling by Eastern Michigan District Court Judge Denise Hood to allow eight cases in Louisiana to be completed in that state while the remaining 1,792 pending cases against Dow Corning shareholders Dow Chemical and Corning are transferred to the Michigan court, where all breast implant suits filed against Dow Corning are being examined under bankruptcy proceedings initiated in May 1995. The writ also seeks clarification from the court on whether findings of the Louisiana court can apply to those cases not yet underway in Michigan. A May 8 decision by the Cincinnati appeals court ordered Hood to consolidate in Michigan all outstanding cases against Dow Chemical. On Nov. 10, the U.S. Supreme Court denied a plaintiffs' petition for a writ of certiorari requesting that the high court review the May 8 ruling...
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.